Skip to main content
OpenTrials
Completed

NCT Number: NCT02298023

Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)

Main purpose of this study is to evaluate efficacy of allogenic adipose-derived mesenchymal stem cells in treatment of tendon injury. ALLO-ASC will be administrated to the patients with supraspinatus partial thickness tear by ultrasonographic guided injection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Seoul National University College of Medicine

Seoul, South Korea

About this study

Injection volume depends on the size of lesion on ultrasound examination. And all injection will be done under ultrasound guidance. Double blind Randomized placebo controlled study will be done with following 3 groups. Each group will have 8 people, so, the total patients will be 24 people.

  • Stem cell treatment group : stem cell 0.5cc (Total: 10 million cells) + Fibrin glue 0.5cc + range of motion exercise
  • Active control (fibrin glue) group : Normal saline 0.5cc + Fibrin glue 0.5cc + range of motion exercise
  • Control (normal saline) group : Normal saline 0.5cc + Normal saline 0.5cc + range of motion exercise

The investigators will compare the efficacy difference with VAS(visual analog scale, primary outcome), ASES(American Shoulder and Elbow Surgeons) Score, UCLA(University of California, Los Angles) Shoulder Score, DASH(The Disabilities of the Arm, Shoulder and Hand) Score and change of tear size compared to the baseline image assessed by MRI. These measurement will be done at 6 and 12 weeks after injections and long-term follow-up will be also planned to 6 months, 12months and 24 months except for the evaluation of the tear size which will be done at baseline, 3 months and 24 months after the intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • clinically diagnosed as rotator cuff tear (supraspinatus partial thickness tear)
  • recurrent pain in spite of conservative treatment such as physical therapy, medication, steroid injection
  • symptom duration is over 3 months
  • supraspinatus partial thickness tear proven ultrasonography and magnetic resonance image(MRI)
  • patient that can understand the clinical trials

Exclusion criteria

  • patient that underwent other injection treatment within 6 weeks
  • some associated diseases (adhesive capsulitis, full thickness supraspinatus tear,. arthritis of related joint to the target lesion, muscle weakness or atrophy, innervated by suprascapular nerve, paralysis of related joint to target lesion, proximal humeral fracture, infectious disease, bilateral rotator cuff tear, generalized pain syndrome, radiculopathy, rheumatoid arthritis, impaired sensibility, dementia, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue and contraindication to MRI
  • patient that enrolled other clinical trials within 30 days
  • history of drug/alcohol addiction, habitual smoker, operation, allergic reaction to fibrin glue, local anesthetics and bovine-derived proteins and severe medical disease.

Treatment and study plan

allogenic adipose stem cell injection

Biological

Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.

Other names: experimental group

fibrin glue/normal saline injection

Biological

Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise

Other names: active control group

Normal saline injection

Biological

Total 1cc of normal saline injection and range of motion exercise

Other names: placebo group

Primary outcomes

  1. Change of Pain During Activity From Baseline to 3 Months After Intervention

    Time frame: Baseline and 3 months after intervention

    Pain during activity will be evaluated by visual analog scale (active pain VAS). The active pain visual analog scale change from baseline to 3 months after intervention is the primary outcome. Visual analog scale is scored 0 to 10, higher scored meaning worse outcome. Negative values in change of pain during activity indicate improvement in pain.

Secondary outcomes

  1. Pain During Rest

    Time frame: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention

    Pain during rest assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome.

  2. Pain During Activity

    Time frame: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention

    Pain during activity assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome

  3. American Shoulder and Elbow Surgeons (ASES) Shoulder Score

    Time frame: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention

    Functional score of the shoulder was assessed by American Shoulder and Elbow Surgeons shoulder score which is a questionnaire dedicated to the functional evaluation of the shoulder. It is scored from 0 to 100, higher scores meaning better outcome.

  4. Disability of Arm, Shoulder and Hand (DASH) Score

    Time frame: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention

    Shoulder function is assessed by DASH score which is questionnaire dedicated to evaluate the function of the upper extremity. It is scored from 0 (no disability) to 100 (most severe disability).

  5. University of California, Los Angeles(UCLA) Shoulder Score

    Time frame: Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention

    Shoulder function is assessed by UCLA shoulder score which is a composite of range of motion examination and questionnaire dedicated to evaluate the function of the shoulder. It is scored from 0 to 35, higher scores meaning better shoulder function.

  6. Tear Size at 3 Months After Injection

    Time frame: baseline and 3 months after intervention

    Tear size was evaluated by 3-point Likert scale using MRI. The 3months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.

  7. Tear Size at 12 Months After Injection

    Time frame: baseline and12 months after intervention

    Tear size was evaluated by 3-point Likert scale using MRI. The 12 months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.

Important dates

Study start
2014
Primary completion
2016
Study completion
2018
First posted
Nov 21, 2014
Registry last updated
Oct 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.